Skip to Main Content

Paper Details

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Blood
81
2021
Author NameAffiliation
Jorge CortesMD Anderson Cancer Center Houston
Hagop KantarjianComprehensive Cancer Center, University of Michigan ann arbor
Michael W DeiningerHuntsman Cancer Institute, University of Utah
  • 1 - 3

Datasets

Release 1.2